Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 26, 2021, reports on events occurring on August 24 and August 25, 2021. Protalix Biotherapeutics, Inc. (the "Company") entered into definitive agreements to exchange a significant portion of its outstanding 7.50% Senior Secured Convertible Notes due 2021 ("Existing Notes") for new 7.50% Senior Secured Convertible Notes due 2024 ("Exchange Notes"), cash, and accrued interest.
Key Financial Metrics and Transaction Details
- Debt Exchange Volume: The Company exchanged an aggregate of $54.65 million principal amount of Existing Notes.
- New Debt Issuance: In exchange, the Company issued $28.75 million principal amount of Exchange Notes due September 1, 2024.
- Cash Consideration: The Company paid approximately $25.90 million in cash plus approximately $1.1 million in accrued and unpaid interest on the Existing Notes.
- Remaining Existing Debt: Following the exchange, $3.27 million aggregate principal amount of the Existing Notes remains outstanding.
- Interest Rate: Both the Existing Notes and Exchange Notes bear interest at 7.50% per annum, payable semi-annually.
- Conversion Terms: The initial conversion rate for Exchange Notes is 563.2216 shares of Common Stock per $1,000 principal amount (equivalent to a conversion price of $1.7755 per share).
- Security: The Exchange Notes are secured by perfected liens on all material assets of the Company and its subsidiaries, at equal priority to the Existing Notes.
Material Changes Versus Prior Period
The primary material change is the extension of the maturity date for the majority of the Company's convertible debt from 2021 to 2024. This transaction significantly reduced the immediate cash repayment obligation due in 2021 by converting a portion of the debt into new notes and paying down the remainder in cash. The transaction required the execution of a Third Supplemental Indenture, approved by holders of 77% of the Existing Notes.
Guidance, Outlook, and Risks
- Settlement Method: Until stockholder approval is obtained to issue additional shares upon conversion, the Company is required to settle at least a portion of its conversion obligation in cash. The Company intends to seek stockholder approval promptly.
- Covenants: The new Indenture includes customary covenants restricting the Company's ability to incur additional indebtedness, create liens, pay dividends, or make restricted payments.
- Redemption Requirement: The Company must apply a portion of proceeds from certain asset sales or licensing arrangements to redeem the Notes.
- Unregistered Sale: The Exchange Notes were issued in reliance on Section 3(a)(9) of the Securities Act of 1933 and are not registered. They may not be offered or sold in the United States except pursuant to an exemption.
Key Facts for Investor Verification
- Verify the Company's current cash position to assess its ability to meet the $25.90 million cash payment and future interest obligations.
- Monitor the status of the stockholder vote required to allow full settlement of conversions in Common Stock rather than cash.
- Review the remaining $3.27 million of Existing Notes due in 2021 and the Company's plan to satisfy that obligation.
- Confirm the impact of the new covenants on the Company's operational flexibility and ability to raise future capital.